Table 3.

Univariate and Multivariate Survival Analysis of OS and DFS in CRCs

	Overall survival										Disease free survival
Variables	Univariate analysis						Multivariate analysis				Univariate analysis						Multivariate analysis
	Median OS		Hazard ratio (95% CI)		P value		Hazard ratio (95% CI)		P value		Median DFS		Hazard ratio (95% CI)		P value		Hazard ratio (95% CI)		P value
Age classes
<60 y (R)	38		1								48		1
≥60 y	45		0.943 (0.615-1.45)		0.787						51		1.24 (0.683-2.25)		0.478
Sex
Male (R)	43		1								52		1
Female	38		1.095 (0.729-1.64)		0.662						48		1.27 (0.587-2.75)		0.544
Site
Right (R)	45		1								40		1
Left	40		0.893 (0.582-1.37)		0.603						48		0.723 (0.369-1.41)		0.343
Size
<6 (R)	37		1								42		1
>6	51		0.756 (0.497-1.152)		0.193						53		0.900 (0.497-1.63)		0.727
Histological type
Adenocarcinoma NOS	43		1.007 (0.548-1.85)		0.981						51		1.29 (0.681-2.47)		0.429
Mucinous adenocarcinoma	34		1.48 (0.599-3.67)		0.394						55		2.13 (0.764-5.95)		0.148
Signet ring carcinoma (R)	27		1								32		1
Adenocarcinoma grade
Low	43		0.265 (0.078-0.901)		0.03*		0.333 (0.095-1.17)		0.086		51		0.171 (0.036-0.809)		0.026*		0.451 (0.117-1.73)		0.246
High(R)	12		1				1				12		1				1
TILs
Low (R)	29		1				1				33		1
Moderate	53		0.517 (0.315-0.849)		0.009*		1.24 (0.703-2.2)		0.454		54		0.834 (0.325-2.14)		0.706
High	53		0.598 (0.340-1.05)		0.074		0.825 (0.428-1.59)		0.565		54		0.654 (0.256-1.67		0.374
Tumor budding
Low (R)	48		1								51		1				1
Moderate	34		0.742 (0.418-1.318)		0.309						34		2.37 (1.04-5.43)		0.04*		1.79 (0.911-3.54)		0.091
High	30		1.35 (0.705-2.55)		0.364						38		0.708 (0.188-2.66)		0.609		0.945 (0.391-2.29		0.9
LVI
Absent (R)		54		1								54		1
Present		34		1.04 (0.565-1.91)		0.903						43		0.986 (0.496-1.96)		0.968
PNI
Absent (R)		48		1								50		1
Present		34		0.946 (0.580-1.54)		0.823						48		1.18 (0.576-2.43)		0.646
T (depth of invasion)
T2		59		1.93 (0.809-4.60)		0.078		1.71 (0.418-7.02)		0.457		55		0.796 (0.134-4.72)		0.805
T3		39		4.43 (1.20-16.35)		0.025*		0.895 (0.416-1.93)		0.778		48		0.455 (0.161-1.29)		0.139
T4(R)		49		1				1				53		1
N (lymph node stage)
N0		54		1.815 (0.171-19.23)		0.799						54		0.14 (0.08-7.2)		0.99
N1		27		1.41 (0.460-4.32)		0.621						37		4.56 (0.850-24.51)		0.08
N2(R)		32		1										1
M (Metastasis stage)
M 0		45		0.427 (0.144-1.27)		0.125						50		7.90 (3.1-9.8)		0.99
M 1(R)		24		1								50		1
AJCC stage
stage I		52		2.9 (0.28-13.7)		0.067		7.9 (0.25-12.69)		0.881		56		0.897 (0.059-13.52)		0.937
stage II		53		0.069 (0.005-0.893)		0.04*		8.2 (0.15-10.44)		0.876		53		0.962 (0.087-10.60)		0.975
Stage III		34		0.302 (0.03-2.75)		0.288		9.1 (0.14-13.19)		0.867		34		1
Stage IV ®		24		1				1
CD8
<60		40		0.769 (0.470-1.26)		0.298						51		0.643 (0.316-1.31)		0.222
>60 (R)		43		1								48		1
HHLA2
Low (R)		57		1				1				55		1				1
High		32		1.74 (1.03-2.96)		0.039*		1.81 (1.06-3.07)		0.03*		29		2.06 (1.24-3.42)		0.005*		1.90 (1.18-3.06)		0.008*

Kaplan-Meier test, used to calculate OS and DFS to detect effect of risk factors on survival. Cox regression was used to assess predictors of survival with calculation of Hazard ratio